| Malaria Journal | |
| The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity | |
| Research | |
| Anders Wallqvist1  Sidhartha Chaudhury1  Jason A. Regules2  Erik Jongert3  Norman C. Waters4  Sheetij Dutta4  Elke Bergmann-Leitner4  Franck Lemiale5  Christian F. Ockenhouse5  | |
| [1] Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, USA;Department of Clinical Research, United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, MD, USA;GSK Vaccine, Rixensart, Belgium;Malaria Vaccine Branch, U.S. Military Malaria Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, 3W53, 20910, Silver Spring, MD, USA;PATH Malaria Vaccine Initiative, Washington, DC, USA; | |
| 关键词: Malaria; Antibody; Phagocytosis; Epitope; Protection; | |
| DOI : 10.1186/s12936-016-1348-9 | |
| received in 2016-03-18, accepted in 2016-05-18, 发布年份 2016 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundRecent vaccine studies have shown that the magnitude of an antibody response is often insufficient to explain efficacy, suggesting that characteristics regarding the quality of the antibody response, such as its fine specificity and functional activity, may play a major role in protection. Previous studies of the lead malaria vaccine candidate, RTS,S, have shown that circumsporozoite protein (CSP)-specific antibodies and CD4+ T cell responses are associated with protection, however the role of fine specificity and biological function of CSP-specific antibodies remains to be elucidated. Here, the relationship between fine specificity, opsonization-dependent phagocytic activity and protection in RTS,S-induced antibodies is explored.MethodsA new method for measuring the phagocytic activity mediated by CSP-specific antibodies in THP-1 cells is presented and applied to samples from a recently completed phase 2 RTS,S/AS01 clinical trial. The fine specificity of the antibody response was assessed using ELISA against three antigen constructs of CSP: the central repeat region, the C-terminal domain and the full-length protein. A multi-parameter analysis of phagocytic activity and fine-specificity data was carried out to identify potential correlates of protection in RTS,S.ResultsResults from the newly developed assay revealed that serum samples from RTS,S recipients displayed a wide range of robust and repeatable phagocytic activity. Phagocytic activity was correlated with full-length CSP and C-terminal specific antibody titres, but not to repeat region antibody titres, suggesting that phagocytic activity is primarily driven by C-terminal antibodies. Although no significant difference in overall phagocytic activity was observed with respect to protection, phagocytic activity expressed as ‘opsonization index’, a relative measure that normalizes phagocytic activity with CS antibody titres, was found to be significantly lower in protected subjects than non-protected subjects.ConclusionsOpsonization index was identified as a surrogate marker of protection induced by the RTS,S/AS01 vaccine and determined how antibody fine specificity is linked to opsonization activity. These findings suggest that the role of opsonization in protection in the RTS,S vaccine may be more complex than previously thought, and demonstrate how integrating multiple immune measures can provide insight into underlying mechanisms of immunity and protection.
【 授权许可】
CC BY
© The Author(s) 2016
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311108370214ZK.pdf | 1700KB | ||
| 12951_2017_255_Article_IEq48.gif | 1KB | Image | |
| Fig. 1 | 334KB | Image |
【 图 表 】
Fig. 1
12951_2017_255_Article_IEq48.gif
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
PDF